I te 1 o Mei, 2025, i panuitia e Hansoh Pharmaceutical kua whakaaetia te werohanga HS-20089 i whakawhanakehia e te Rōpū hei rongoā Breakthrough-Therapy-Tohu e te National Medical Products Administration (NMPA) o Haina, me te tohu kua whakaarohia mō te mate pukupuku ovarian epithelial ātete-platinum, te mate pukupuku ngongo fallopian, te mate pukupuku peritoneal tuatahi rānei.
E tautokona ana te tohu e ngā hua o te rangahau Wāhanga I HS-20089-101 me te rangahau Wāhanga II HS-20089-201. Ko te rangahau HS-20089-101 he whakamātautau haumanu Wāhanga I tuwhera-tohu maha-pokapū hei aromatawai i te haumaru, te manawanui, te pharmacokinetics, me te whai huatanga o te HS-20089 mō te werohanga i roto i ngā tūroro he pukupuku totoka kua whanake haere. Ko te rangahau HS-20089-201 he whakamātautau haumanu Wāhanga II tuwhera-tohu maha-pokapū hei aromatawai i te whai huatanga, te haumaru, te kōtaha pharmacokinetic, me te ārai mate o te HS-20089 werohanga ā-uaua i roto i ngā tūroro he mate pukupuku ovarian e hokihoki ana, e horapa ana rānei, me te mate pukupuku endometrial.
Ko te HS-20089 he ADC e arohia ana ki te B7-H4 me te kawenga aukati topoisomerase (TOPOi) e whakawhanakehia ana mō te rongoā i te mate pukupuku ovarian me ētahi atu pukupuku wahine i roto i ngā whakamātautau haumanu maha i Haina, ko te wāhanga rangahau teitei rawa ko ngā whakamātautau haumanu Wāhanga III. Ko te B7-H4 he glycoprotein ārai mate transmembrane e tino whakaatuhia ana i roto i ngā pukupuku totoka maha, tae atu ki te mate pukupuku endometrial me te mate pukupuku ovarian, engari he iti noa te whakaaturanga i roto i ngā kiko noa.
I tēnei wā, he maha tonu ngā whakamātautau haumanu o ngā hangarau hou hei ārai i te matepukupuku i Haina e rapu ana i ngā tūroro. Mēnā kei te hiahia koe ki te kōrero mō ngā rongoā me ngā hangarau hou, ka taea e koe te whakapā atu ki te Tari Ao o te Hōhipera Oncology Rohe Tonga o Beijing.
Tau Waea：4008803716
Īmēra：myimmnet@163.com
Wā tuku: Mei-09-2025